

## DAFTAR PUSTAKA

- Abraham, G. And Ravichandran, R., 2005, Efficacy and Tolerability of Sevelamer in the Treatment of Hyperphosphatemia in Indian Patients on Dialysis, *Indian J Nephrol*, **15**:198-204.
- Allredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A. *et al.*, 2013, *Koda Kimble and Young's Applied Therapeutics The Clinical Use of Drugs*, 10<sup>th</sup> ed., Lippincott Williams and Wilkins, USA, pp 662, 784-787.
- Alomar, M.J., 2014, Factors Affecting the Development of Adverse Drug Reactions, *Saudi Pharmaceutical Journal*, **22**: 83–94.
- American Pharmacists Association, 2009, *Drug Information Handbook*, 17<sup>th</sup> edition, Lexi-Comp, APhA, USA.
- American Pharmacists Association, 2016, *Drug Information Handbook*, 25<sup>th</sup> edition, Lexi-Comp, APhA, USA.
- Anonim, 2016, *Renagel*, diakses dari <http://www.rxlist.com/renagel-drug/clinical-pharmacology.htm> pada tanggal 20 April 2016.
- Anonim, 2017, *Renvela (sevelamer carbonate tablets) Product Monograph*, Sanofi-Aventis Canada Inc., Laval, Quebec.
- Asmus, H., Braun, J., Krause, R., Brunkhorst, R., Holzer, H., Schulz, W. *et al.*, 2005, Two Year Comparison of Sevelamer and Calcium Carbonate Effects on Cardiovascular Calcification and Bone Density, *Nephrol Dial Transplant*, **20**: 1653–1661.
- Badan POM RI, 2012, *Pedoman Monitoring Efek Samping Obat (MESO) bagi Tenaga Kesehatan*, Badan POM RI, Jakarta, Indonesia.
- Balai Penelitian dan Pengembangan Kesehatan, 2013, *Riset Kesehatan Dasar (RISKESDAS)*, Kementerian Kesehatan RI, Jakarta, Indonesia.
- Barone, J.A and Hermes-DeSantis, E.R., 2000, 'Adverse Drug Reaction and Drug Induced Disease', in Herfindal, E.T. and Gourley, D.R., *Textbook of Therapeutics: Drug and Disease Management*, 7th ed., Lippincott William and Wilkins, Philadelphia, pp 32-34.
- Baxter, K., 2008, *Stockley's Drug Interactions*, 8<sup>th</sup> ed., Pharmaceutical Press, UK.
- Block, G.A., Spiegel, D.M., Ehrlich, J., Mehta, R., Lindbergh, J., Dreicbach, A. *et al.*, 2005, Effects of Sevelamer and Calcium on Coronary Artery Calcification in Patients New to Hemodialysis, *Kidney International*, **68**: 1815-24.
- Burke, S.K., Amin, N.S., Incerti, C., Plone, M.A., Lee, J.W, 2001a, Sevelamer Hydrochloride (Renagel), A Phosphate-binding Polymer, does not Alter

the Pharmacokinetics of Two Commonly Used Antihypertensives in Healthy Volunteers, *J Clin Pharmacol*, **41**:199–205.

Burke, S.K., Amin, N.S., Incerti, C., Plone, M.A., Watson, N., 2001b, Sevelamer Hydrochloride (Renagel), a Nonabsorbed Phosphate-binding Polymer, does not Interfere with Digoxin or Warfarin Pharmacokinetics, *J Clin Pharmacol*, **41**:193–198.

Center for Disease Control and Prevention (CDC), 2014, 'National Chronic Kidney Disease Fact Sheet', diakses pada 3 Maret 2016, <[http://www.cdc.gov/diabetes/pubs/pdf/kidney\\_factsheet.pdf](http://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf)>.

Cipolle, R.J., Strand, L.M., Morley, P.C., 2004, Drug Therapy Problems, dalam *Pharmaceutical Care Practice: The Clinician's Guide*, 2<sup>nd</sup> Edition, The McGraw-Hill Companies, New York, USA.

Chintamaneni, P., Das, R., Kuan, S-F., Kermanshahi, T.R., Hashash, J.G., 2014, Hematochezia Associated with Sevelamer-Induced Mucosal Injury, *ACG Case Reports Journal*, **1**:145–147.

Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G. and Posey, L.M., 2008, *Pharmacotherapy: A Pathophysiologic Approach*, 7<sup>th</sup> ed., The McGraw-Hill Companies Inc., New York, USA.

Duncombe, D., Wertheim, E.H., Skouteris, H., Paxton, S.J., Kelly, L., 2008, How Well Do Women Adapt to Changes in Their Body Size and Shape Across the Course of Pregnancy, *J. Health Psychol.*, **13**: 503–515.

Edwards, I.R. & Aronson, J.K., 2000, Adverse Drug Reactions: Definitions, Diagnosis, and Management, *Lancet*, **356**: 1255–59.

El-Eraky, H., Thomas, S.H.L., 2003, Effects of Sex on the Pharmacokinetic and Pharmacodynamic Properties of Quinidine, *Br. J. Clin. Pharmacol.*, **56**: 198–204.

Evenepoel, P., Selgas, R., Caputo, F., Foggensteiner, L., Heaf, J.G., Ortiz, A. et al., 2008, Efficacy and Safety of Sevelamer Hydrochloride and Calcium Acetate in Patients on Peritoneal Dialysis, *Nephrol Dial Transplant*, 1-8.

Filho, E.J.D., da Cruz, E.D.S., Hoette, M., Ruzany, F., Keen, L.N.L., Lugon, J.R., 2000, Calcium Acetate versus Calcium Carbonate in the Control of Hyperphosphatemia in Hemodialysis Patients, *Sao Paulo Med J/Rev Paul Med*, **118**: 179-84.

Fincham, J.E., 1991, An Overview of Adverse Drug Reactions, *Am Pharm NS*, **31**:47–52 cit. Barone, J.A and Hermes-DeSantis, E.R., 2000, 'Adverse Drug Reaction and Drug Induced Disease', in Herfindal, E.T. and Gourley, D.R., *Textbook of Therapeutics: Drug and Disease Management*, 7th ed., Lippincott William and Wilkins, Philadelphia, pp 32-34.

Guillen-Anaya, M.A. and Jadoul, M., 2004, Drug Interaction between Sevelamer and Cyclosporin, *Nephrol Dial Transplant*, **19**:1939–1940.

- Grubb, M., Gaurav, K., Panda, M., 2009, Milk-alkali Syndrome in a Middle-aged Woman after Ingesting Large Doses of Calcium Carbonate: A Case Report, *Cases Journal*, **2**: 8198.
- Hervas, J.G., Prados, D. and Cerezo, S., 2003, Treatment of Hyperphosphatemia with Sevelamer Hydrochloride in Hemodialysis Patients: A Comparison with Calcium Acetate, *Kidney International*, **63**:S69-S72.
- Horn, J.R., Hansten, P.D, Chan, L.N., 2007, Proposal for a New Tool to Evaluate Drug Interaction Cases, *The Annals of Pharmacotherapy*, **41**:674-680.
- Jamal, S.A., Vandermeer, B., Raggi, P., Mendelssohn, D.C., Chatterley, T., Dorgan, M. *et al.*, 2013, Effect of Calcium-based versus Non-calcium-based Phosphate Binders on Mortality in Patients with Chronic Kidney Disease: An Update Systematic Review and Meta-analysis, *www.thelancet.com*, **382**:1268-1277.
- Jindal, K., Chan, C.T., Deziel, C., Hirsch, D., Soroka, S.D., Tonelli, M. *et al.*, 2006, Chapter 3: Mineral Metabolism, *J Am Soc Nephrol*, **17**: S11–S14.
- Karch, F.E. and Lasagna, L., 1975, Adverse Drug Reactions: A Critical Review, *JAMA*, **234**:1236–1241 cit. Barone, J.A and Hermes-DeSantis, E.R., 2000, ‘Adverse Drug Reaction and Drug Induced Disease’, in Herfindal, E.T. and Gourley, D.R., *Textbook of Therapeutics: Drug and Disease Management*, 7<sup>th</sup> ed., Lippincott William and Wilkins, Philadelphia, pp 32.
- Kays, M.B., Overholser, B.R., Mueller, B.A., Moe, S.M., Sowinski, K.M., 2003, Effects of Sevelamer Hydrochloride and Calcium Acetate on the Oral Bioavailability of Ciprofloxacin, *Am J Kidney Dis*, **42**:1253–1259.
- Kestenbaum, B., Sampson, J.N., Rudser, K.D., Patterson, D.J., Seliger, S.L., Young, B. *et al.*, 2005, Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease, *J Am Soc Nephrol*, **16**: 520-528.
- Kidney Disease Improving Global Outcomes (KDIGO), 2012, Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, *Journal of the International Society of Nephrology*, **3**: 5-8.
- Kurnik, D., Loebstein, R., Farfel, Z., Ezra, D., Halkin, H., Olchovsky, D., 2004, Complex Drug–drug-disease Interactions Between Amiodarone, Warfarin, and the Thyroid Gland, *Medicine*, **83**: 107–113.
- Lacour, B., Lucas, A., Auchere, D., Ruellan, N., de Serre Patey, N.M., Drueke, T.B., 2005, Chronic Renal Failure is associated with Increased Tissue Deposition of Lanthanum after 28-day Oral Administration, *Kidney Int*, **67**:1062-1069.
- Lazarou, J., Pomeranz, B.H. and Corey, P.N., 1998, Incidence of Adverse Drug Reactions in Hospitalized Patients A Meta-analysis of Prospective Studies, *JAMA*, **279**:1200-1205 cit. Barone, J.A and Hermes-DeSantis,

- E.R., 2000, 'Adverse Drug Reaction and Drug Induced Disease', in Herfindal, E.T. and Gourley, D.R., *Textbook of Therapeutics: Drug and Disease Management*, 7<sup>th</sup> ed., Lippincott William and Wilkins, Philadelphia, pp 33.
- Lemeshow, S., Hosmer, J., Klar, J., dan Lwanga, S., 1997. *Besar Sampel Dalam Penelitian Kesehatan, Diterjemahkan Dari Bahasa Inggris Oleh Pramono, D.* UGM Press, Yogyakarta.
- London, G.M., Marty, C., Marchais, S.J., Guerin, A.P., Metivier, F., de Vernejoul, M.C., 2004, Arterial calcification and bone histomorphometry in end stage renal disease, *J Am Soc Nephrol*, **15**:1943-1951.
- Mardiana, N. dan Aditiawardana, 2015, 'Penyakit Ginjal Kronis', dalam Tjokroprawiro, A. (ed), *Buku Ajar Ilmu Penyakit Dalam*, Edisi 2, Airlangga University Press, Indonesia.
- Naranjo, C.A., Busto, U., Sellars, E.M., Sandor, P., Ruiz, I., Roberts, E.A. *et al.*, 1981, A Method for Estimating the Probability of Adverse Drug Reactions, *Clinical Pharmacology and Therapeutics*, **30**:239-245 cit. Doherty, M.J., 2009, Algorithms for Assessing the Probability of an Adverse Drug Reaction, *Respiratory Medicine CME* **2**, 63-67.
- Navaneethan, S.D., Palmer, S.C., Craig, J.C., Elder, G.J., Strippoli, G.F.M., 2009, Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials, *American Journal of Kidney Diseases*, **54**: 619-637.
- Palmer, R.J., Butenhoff, J.L., Stevens, J.B., 1987, Cytotoxicity of the Rare Earth Metals Cerium, Lanthanum, and Neodymium in Vitro: Comparisons with Cadmium in a Pulmonary Macrophage Primary Culture System, *Environ Res*, **43**:142-156.
- Palmer, S.C., Gardner, S., Tonelli, M., Mavridis, D., Johnson, D.W., Craig, J.C. *et al.*, 2016, Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials, *Am J Kidney Dis*, 1-12.
- Perkumpulan Nefrologi Indonesia (PERNEFRI), 2012, '5th Report of Indonesian Renal Registry', diakses pada 17 Maret 2016, <<http://www.pernefri-inasn.org/Laporan/5th%20Annual%20Report%20Of%20IRR%202012.pdf>>.
- Picolos, M.K. and Orlander, P.R., 2005, Calcium Carbonate Toxicity: The Updated Milk-alkali Syndrome; Report of 3 Cases and Review of the Literature, *Endocr Pract*, **11**:272-280.
- Pieter, E., Rafael, S., Flavia, C., Lukas, F., James, G.H., Alberto, O. *et al.*, 2008, Efficacy and Safety of Sevelamer Hydrochloride and Calcium Acetate in Patients on Peritoneal Dialysis, *Nephrol Dial Transplant*, 1-8.

- Pohlmeier and Vienken, 2001, Phosphate removal and hemodialysis conditions, *Kidney Int Suppl.*, **78**: S190-4.
- Salusky, I.B., 2006, A new era in phosphate binder therapy: What are the options?, *Kidney International*, **70**:S10-S15.
- Schatz, S.N. and Webber, R.J., 2015, Adverse Drug Reactions, *PSAP*, 1-22.
- Schumock, G.T. and Thornton, J.P., 1992, Focusing on Preventability of Adverse Drug Reactions, *Clin Pharmacol Ther*, **30**:239–245, cit. Barone, J.A and Hermes-DeSantis, E.R., 2000, ‘Adverse Drug Reaction and Drug Induced Disease’, in Herfindal, E.T. and Gourley, D.R., *Textbook of Therapeutics: Drug and Disease Management*, 7<sup>th</sup> ed., Lippincott William and Wilkins, Philadelphia, pp 33.
- Sexton, J.B., Thomas, E.J., Helmreich, R.L., 2000, Error, Stress, and Teamwork in Medicine and Aviation: Cross-sectional Surveys, *BMJ*, **320**:745–749.
- Shailaja, K., Ramasamy, C., Kuriakose, S. and Sureshababu, L., 2013, The Safety and Efficacy of Phosphate Binders in Dialysis Patients, *International Journal of Pharmacy and Pharmaceutical Sciences*, **5**:360-362.
- Shaheen, F.A., Akeel, N.M., Badawi, L.S., Souqiyyeh, M.Z., 2004, Efficacy and Safety of Sevelamer, Comparison with Calcium Carbonate in the Treatment of Hyperphosphatemia in Hemodialysis Patients, *Saudi Med J*, **25**:785-791.
- Sheikh, M.S., Maguire, J.A., Emmett, M. *et al.*, 1989, Reduction of Dietary Phosphorus Absorption by Phosphorus Binders. A Theoretical in Vitro and in Vivo Study., *J Clin Invest*, **83**: 66–73, cit Salusky, I.B., 2006, A New Era in Phosphate Binder Therapy: What are the options?, *Kidney International*, **70**: S10–S15.
- Singh, A. and Ashraf, A., 2012, Hypercalcemic Crisis Induced by Calcium Carbonate, *Clin Kidney J*, **5**: 288-291.
- Subramanian, C.R. and Roorda, A., 2016, GI Mucosal Injury and Bleeding: Association with Sevelamer Crystals, *Gastrointest Dig Syst*, **6**:409.
- Suki, W.N., Zabaneh, R., Cangiano, J.L., Reed, J., Fischer, D., Garrett, L. *et al.*, 2007, Effects of Sevelamer and Calcium-based Phosphate Binders on Mortality in Hemodialysis Patients, *Kidney International*, **72**:1130-1137.
- Sun, H., Frassetto, L., Benet, L.Z., 2006, Effects of Renal Failure on Drug Transport and Metabolism, *Pharmacol Ther*, **109**:1–11.
- Tatro, D.S., 2009, *Drug Interaction Facts The Authority on Drug Interactions*, Wolters Kluwer Health Inc, California.
- Tieu, C., Moreira, R.K., Wong, L.M., Majumder, S., Papadakis, K.A., Hogan, M.C., 2016, A Case Report of Sevelamer-associated Recto-sigmoid Ulcers, *BMC Gastroenterology*, **16**:20-23.

- Tomlinson, J.E., McMahon, A.D., Chaudhuri, R., 2005, Efficacy of Low and High Dose Inhaled Corticosteroid in Smokers versus Nonsmokers with Mild Asthma, *Thorax*, **60**:282–287.
- Tonelli, M., Natasha, W., Bruce, C., Helen, L., Scott, K., Fiona, S. *et al.*, 2007, Systematic Review of the Clinical Efficacy and Safety of Sevelamer in Dialysis Patients, *Nephrol Dial Transplant*, **22**:2856-2866.
- Venitz, R., 2000, Effect of Chronic Renal Failure on the Disposition of Highly Hepatically Metabolized Drugs, *Int J Clin Pharmacol Ther*, **38**: 245–253.
- Wang, Y., Xie, G., Huang, Y., Zhang, H., Yang, B., Mao, Z., 2015, Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis, *PLOS ONE*.
- Zacharias, J.M., Fontaine, B., and Fine, A., 1999, Calcium Increases Risk of Calciphylaxis: A Case Control Study, *Perit Dial Int*, **19**:248-252.
- Zhang, C., Wen, J., Li, Z., Fan, J., 2013, Efficacy and Safety of Lanthanum Carbonate on Chronic Kidney Disease–Mineral and Bone Disorder in Dialysis Patients: A Systematic Review, *BMC Nephrology*, **14**:226.